the data revealed a highly significant reduction in climacteric symptoms in the hormone-treated women as compared with the placebo group ( p less than 0.001 ) , a highly significant dose relationship between climacteric symptoms and treatment with 4 , 2 and 1 mg oestradiol , respectively ( p less than 0.001 ) , a highly significant and dose-dependent rebound phenomenon after withdrawal of hormone treatment ( p less than 0.001 ) -- which levelled off after 6 mth following withdrawal -- and complete relief of hot flushes with the two highest doses of oestradiol ( 4 and 2 mg oestradiol ) .
C0600142
hot flushes
C0014912
oestradiol